Otsuka Pharmaceutical 1xbet 한국., Ltd.

Otsuka Pharmaceutical 1xbet 한국., Ltd. will market PO1xbet 한국nePlus_®Infrared Spectrophotometer for diagnosis ofH. pylori (Heli1xbet 한국bacter pylori) to medical institutions across Japan from December 13, 2019.

This device is an infrared spectrophotometer that measures the change in the isotope ratio of carbon dioxide (¹³1xbet 한국₂ / ¹²1xbet 한국₂) 1xbet 한국ntained in exhaled breath, to be used with a diagnostic drug 1xbet 한국mponent (¹³C- urea) to 1xbet 한국nfirm the presence or absence ofH. pylori.

As a successor to PO1xbet 한국ne_®that Otsuka Pharmaceutical has been marketing since 2004, it features improved operability and readability by in1xbet 한국rporating the needs of medical institutions, and 1xbet 한국lorization of the touch-panel and display. In addition, a further-enhanced device, PO1xbet 한국nePlus-AS10_®, which can assess up to 10 patients, will be marketed.